AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23602325 — intervention group
Group type: COMPARATOR
Intervention: Antiemetics alone
Number of subjects: 500
Study 23747777 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (a factor Xa inhibitor)
Number of subjects: 0
Study 23747777 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (dual antiplatelet therapy)
Number of subjects: 0
Study 20839431 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction combined with internal fixation (n=35)
Number of subjects: 65
Study 20839431 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial radial head replacement (n=30)
Number of subjects: 65
Study 17375118 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin olive oil (50 ml daily)
Number of subjects: 28
Study 17375118 — intervention group
Group type: COMPARATOR
Intervention: Refined olive oil (control)
Number of subjects: 28
Study 16399150 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice-weekly
Number of subjects: 618
Study 16399150 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 618
Study 16399150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study 14581118 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg/kg fentanyl intravenously
Number of subjects: 28
Study 14581118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10737480 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG maintenance therapy (intravesical and percutaneous BCG each week for 3 weeks at 3, 6, 12, 18, 24, 30, and 36 months)
Number of subjects: 384
Study 10737480 — intervention group
Group type: COMPARATOR
Intervention: No BCG maintenance therapy
Number of subjects: 384
Study 10737480 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG maintenance therapy
Number of subjects: 384
Study 8762313 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar diathermy technique
Number of subjects: 105
Study 8762313 — intervention group
Group type: COMPARATOR
Intervention: Ligation technique
Number of subjects: 105
Study 1578910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive consolidation therapy (including allogeneic and autologous bone marrow transplantation)
Number of subjects: 0
Study 1578910 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation
Number of subjects: 0
Study 1578910 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine (3 gm/M2/day IV on days 1-6)
Number of subjects: 0
Study 1578910 — intervention group
Group type: COMPARATOR
Intervention: Conventional induction therapy +/− GM-CSF
Number of subjects: 0
Study 2860167 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily antiseptic mouthwash with chlorhexidine‐gluconate
Number of subjects: 0
Study 2860167 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily antiseptic mouthwash with povidone‐iodine
Number of subjects: 0
Study 2860167 — intervention group
Group type: COMPARATOR
Intervention: Hygienic treatment alone
Number of subjects: 0
Study 31179831 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (20 μg bolus followed by 20 μg/h infusion)
Number of subjects: 24
Study 31179831 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically appearing)
Number of subjects: 24
Study 28393440 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Intervention Group (IIG)
Number of subjects: 77
Study 28393440 — intervention group
Group type: COMPARATOR
Intervention: Delayed Intervention Group (DIG)
Number of subjects: 77
Study 26488141 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum-based advocacy training
Number of subjects: 257
Study 26488141 — intervention group
Group type: COMPARATOR
Intervention: Self-directed advocacy activities
Number of subjects: 257
Study 26488141 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (curriculum and self-directed)
Number of subjects: 257
Study 23759472 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 9248
Study 23759472 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 9248
Study 21816692 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical exercise program (aerobic and anaerobic exercises)
Number of subjects: 84
Study 21816692 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for diabetes
Number of subjects: 84
Study 19539306 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphological derivations with stress changes
Number of subjects: 104
Study 19539306 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosodic sensitivity and morphological awareness
Number of subjects: 104
Study 16458200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (500 mg, twice daily; 2 weeks)
Number of subjects: 24
Study 16458200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16458200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 24
Study 15566336 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling (2 sessions at about 2 months postpartum)
Number of subjects: 162
Study 15566336 — intervention group
Group type: COMPARATOR
Intervention: Control group (no group counseling)
Number of subjects: 162
Study 11710662 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal strip
Number of subjects: 14
Study 11710662 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 11710662 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal strip
Number of subjects: 14
Study 9213203 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol (10 mg q.d.)
Number of subjects: 105
Study 9213203 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril (20 mg q.d.)
Number of subjects: 105
Study 10779310 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/m2 rIFN-gamma
Number of subjects: 20
Study 10779310 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma
Number of subjects: 20
Study 10779310 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 3315914 — intervention group
Group type: EXPERIMENTAL
Intervention: oral ketanserin (20 mg X 7)
Number of subjects: 6
Study 3315914 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 29148822 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactagogue (GG) containing Sylimarin-Phosphatidylserine and Galega
Number of subjects: 100
Study 29148822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PG)
Number of subjects: 100
Study 29148822 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactagogue (GG)
Number of subjects: 100
Study 27132409 — intervention group
Group type: EXPERIMENTAL
Intervention: DermoXEN Ultracalming Special for diabetics
Number of subjects: 48
Study 27132409 — intervention group
Group type: EXPERIMENTAL
Intervention: DermoXEN Vitexyl vaginal gel
Number of subjects: 48
Study 27132409 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 24604487 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care model of follow-up visits in the first 12 months after treatment, including a survivorship care plan, GP management guidelines, register and recall systems, screening for distress and unmet needs, and patient information resources.
Number of subjects: 90
Study 24604487 — intervention group
Group type: COMPARATOR
Intervention: Current hospital follow-up care (Control group).
Number of subjects: 90
Study 23690424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus brivanib 800 mg orally daily
Number of subjects: 750
Study 23690424 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab plus placebo
Number of subjects: 750
Study 20626735 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 34
Study 20626735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 18400707 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA diet (n = 16): moderate in fat (35-45% of energy) and high in monounsaturated fatty acids (> 20% of energy)
Number of subjects: 46
Study 18400707 — intervention group
Group type: COMPARATOR
Intervention: Control diet (n = 12): 35% of energy as fat (> 15% of energy as saturated fatty acids)
Number of subjects: 46
Study 18400707 — intervention group
Group type: COMPARATOR
Intervention: LF diet (n = 18): low-fat diet (20-30% of energy)
Number of subjects: 46
Study 16630383 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly iron supplementation (ferrous dextran, 60 mg elemental iron)
Number of subjects: 329
Study 16630383 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 329
Study 14620026 — intervention group
Group type: EXPERIMENTAL
Intervention: Video model with visual and verbal cues
Number of subjects: 60
Study 14620026 — intervention group
Group type: COMPARATOR
Intervention: Video model with visual cues
Number of subjects: 60
Study 14620026 — intervention group
Group type: COMPARATOR
Intervention: Video model with verbal cues
Number of subjects: 60
Study 14620026 — intervention group
Group type: COMPARATOR
Intervention: Video model only
Number of subjects: 60
Study 14620026 — intervention group
Group type: COMPARATOR
Intervention: Discovery learning
Number of subjects: 60
Study 14620026 — intervention group
Group type: COMPARATOR
Intervention: Verbal instruction
Number of subjects: 60
Study 10942476 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocautery scissors
Number of subjects: 50
Study 10942476 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 50
Study 8911006 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms OprI vaccine
Number of subjects: 28
Study 8911006 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms OprI vaccine
Number of subjects: 28
Study 8911006 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms OprI vaccine
Number of subjects: 28
Study 8911006 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms OprI vaccine
Number of subjects: 28
Study 8911006 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 28
Study 1729038 — intervention group
Group type: COMPARATOR
Intervention: Continuous iv infusion of furosemide (initial dose 0.1 mg/kg iv, infusion rate 0.1 mg/kg.hr, doubled every 2 hrs to max 0.4 mg/kg.hr)
Number of subjects: 0
Study 1729038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent iv infusion of furosemide (1 mg/kg iv every 4 hrs, increased by 0.25 mg/kg every 4 hrs to max 1.5 mg/kg)
Number of subjects: 0
Study 6339571 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopoietin pentapeptide (TP-5) 50 mg, thrice-weekly injections for 6 weeks
Number of subjects: 18
Study 6339571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31607271 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (part of a randomized trial)
Number of subjects: 555
Study 31607271 — intervention group
Group type: EXPERIMENTAL
Intervention: Index case age 1-4 years
Number of subjects: 555
Study 31607271 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfection as initial infection
Number of subjects: 555
Study 31607271 — intervention group
Group type: EXPERIMENTAL
Intervention: No electricity in household
Number of subjects: 555
Study 28085515 — intervention group
Group type: EXPERIMENTAL
Intervention: PNAM
Number of subjects: 84
Study 28085515 — intervention group
Group type: COMPARATOR
Intervention: Non-PNAM
Number of subjects: 84
Study 27179726 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate monitoring using wearable sensors (single-lead electrocardiogram)
Number of subjects: 2100
Study 27179726 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed monitoring using wearable sensors (single-lead electrocardiogram)
Number of subjects: 2100
Study 27179726 — intervention group
Group type: COMPARATOR
Intervention: Observational control group (n = 4,000)
Number of subjects: 2100
Study 25160064 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly standardized SMS
Number of subjects: 348
Study 25160064 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly standardized supervisory visits
Number of subjects: 348
Study 25160064 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 348
Study 18728038 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 148
Study 18728038 — intervention group
Group type: COMPARATOR
Intervention: Non-users of low-dose aspirin (Control)
Number of subjects: 148
Study 15029508 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated contour detection technique for tracing the lumen, outer boundary and plaque contours in carotid MR images
Number of subjects: 17
Study 11087965 — intervention group
Group type: EXPERIMENTAL
Intervention: mCPP (0.5 mg/kg body weight)
Number of subjects: 34
Study 9061893 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively valenced TV news bulletin
Number of subjects: 0
Study 9061893 — intervention group
Group type: COMPARATOR
Intervention: Neutral valenced TV news bulletin
Number of subjects: 0
Study 9061893 — intervention group
Group type: COMPARATOR
Intervention: Positively valenced TV news bulletin
Number of subjects: 0
Study 7524629 — intervention group
Group type: EXPERIMENTAL
Intervention: Lugol's iodine staining technique
Number of subjects: 203
Study 3282893 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg b.i.d. (increased to 10 mg b.i.d. if needed)
Number of subjects: 76
Study 3282893 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg b.i.d. (increased to 25 mg b.i.d. if needed)
Number of subjects: 76
Study 11341663 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee (280 ml)
Number of subjects: 10
Study 11341663 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study 31356537 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg subcutaneously
Number of subjects: 20
Study 31356537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29374995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous injection (IO)
Number of subjects: 60
Study 29374995 — intervention group
Group type: COMPARATOR
Intervention: Inferior alveolar nerve block (IANB) with 3% mepivacaine
Number of subjects: 60
Study 29374995 — intervention group
Group type: COMPARATOR
Intervention: Inferior alveolar nerve block (IANB)
Number of subjects: 60
Study 26329802 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping + exercise (n = 12)
Number of subjects: 24
Study 26329802 — intervention group
Group type: COMPARATOR
Intervention: Exercise (n = 12)
Number of subjects: 24
Study 25392248 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual diagnosis enhanced programs
Number of subjects: 261
Study 25392248 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual diagnosis capable
Number of subjects: 261
Study 25392248 — intervention group
Group type: COMPARATOR
Intervention: Addiction only services
Number of subjects: 261
Study 22130359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless PCNL (group 1)
Number of subjects: 100
Study 22130359 — intervention group
Group type: COMPARATOR
Intervention: Standard PCNL (group 2)
Number of subjects: 100
Study 20665501 — intervention group
Group type: EXPERIMENTAL
Intervention: DCTER regimen (daunorubicin, cytarabine, thioguanine, etoposide, dexamethasone)
Number of subjects: 61
Study 20665501 — intervention group
Group type: COMPARATOR
Intervention: IA combination (idarubicin and cytarabine)
Number of subjects: 61
Study 17602073 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 5 mg/kg infused over 10 minutes
Number of subjects: 1077
Study 17602073 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab 5 mg/kg infused over 30 minutes
Number of subjects: 1077
Study 17602073 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab 5 mg/kg infused at a standard rate of 0.5 mg/kg/min
Number of subjects: 1077
Study 16040284 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (300 mg b.d.)-based therapy with lansoprazole (30 mg b.d.) and amoxicillin (1000 mg b.d.) for 7 days
Number of subjects: 60
Study 16040284 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (500 mg b.d.)-based therapy with lansoprazole (30 mg b.d.) and amoxicillin (1000 mg b.d.) for 7 days
Number of subjects: 60
Study 12556743 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolytic therapy using urokinase
Number of subjects: 63
Study 12556743 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolytic therapy
Number of subjects: 63
Study 12556743 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation with unfractionated or low molecular weight heparin followed by warfarin
Number of subjects: 63
Study 10362203 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Atrial Pacing (RAP)
Number of subjects: 61
Study 10362203 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatrial Pacing (BAP)
Number of subjects: 61
Study 10362203 — intervention group
Group type: COMPARATOR
Intervention: No Atrial Pacing (NAP)
Number of subjects: 61
Study 7795270 — intervention group
Group type: EXPERIMENTAL
Intervention: TMQ at 200 mg/m2 i.v. q 2 weeks
Number of subjects: 162
Study 7795270 — intervention group
Group type: EXPERIMENTAL
Intervention: TMQ at 12 mg/m2 i.v. daily x 5
Number of subjects: 162
Study 7795270 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) at 15 mg/kg i.v. weekly
Number of subjects: 162
Study 2117680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia (PETCO2: 60mmHg)
Number of subjects: 16
Study 2117680 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (PETCO2: 40mmHg)
Number of subjects: 16
Study 6971922 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement of 400 IU/day
Number of subjects: 18
Study 6971922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30879881 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational SMS
Number of subjects: 4386
Study 30879881 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulatory SMS
Number of subjects: 4386
Study 30879881 — intervention group
Group type: COMPARATOR
Intervention: No SMS (Control)
Number of subjects: 4386
Study 29390477 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride (DHC) 80‐mg tablet, 3 times daily for 4 weeks
Number of subjects: 144
Study 29390477 — intervention group
Group type: COMPARATOR
Intervention: Placebo 80‐mg tablet, 3 times daily for 4 weeks
Number of subjects: 144
Study 29390477 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride (DHC)
Number of subjects: 144
Study 29390477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 26021211 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery incision
Number of subjects: 82
Study 26021211 — intervention group
Group type: COMPARATOR
Intervention: Scalpel incision
Number of subjects: 82
Study 24875433 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention
Number of subjects: 142
Study 24875433 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 142
Study 22000773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine (120 μg for the right coronary artery and 180 μg for the left coronary artery)
Number of subjects: 260
Study 22000773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 22000773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine
Number of subjects: 260
Study 19685728 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) of Ashi-point, Jiaji (EX‐B 2), Zhigou (SJ 6) and Houxi (SI 3), once daily for 10 times
Number of subjects: 80
Study 19685728 — intervention group
Group type: COMPARATOR
Intervention: Medication group (valaciclovir hydrochloride 300 mg/time, b.i.d. and vitamin B1 10 mg/time, t.i.d., for 10 days)
Number of subjects: 80
Study 19685728 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 19685728 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group
Number of subjects: 80
Study 18161262 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day
Number of subjects: 4
Study 18161262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 15640898 — intervention group
Group type: EXPERIMENTAL
Intervention: Solanum melongena (SM) 450 mg twice daily
Number of subjects: 41
Study 15640898 — intervention group
Group type: COMPARATOR
Intervention: Placebo 450 mg twice daily
Number of subjects: 41
Study 15640898 — intervention group
Group type: EXPERIMENTAL
Intervention: Solanum melongena (SM)
Number of subjects: 41
Study 15640898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11584350 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone nursing intervention weekly for 3 months
Number of subjects: 15
Study 11584350 — intervention group
Group type: COMPARATOR
Intervention: Informational calls at weeks 6 and 12
Number of subjects: 15
Study 10099041 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (titrated from 8 to 24 mg/d)
Number of subjects: 12
Study 8136389 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypodense solution of mannitol (n = 23)
Number of subjects: 37
Study 8136389 — intervention group
Group type: COMPARATOR
Intervention: Suspension of BaSO4 (n = 14)
Number of subjects: 37
Study 2491962 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (hexamethylmelamine, 5‐fluorouracil, cisplatin, and prednimustine)
Number of subjects: 76
Study 2491962 — intervention group
Group type: COMPARATOR
Intervention: Prednimustine alone
Number of subjects: 76
Study 1091994 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium
Number of subjects: 45
Study 31020550 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (HT) prevalence measurement
Number of subjects: 354
Study 31020550 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension (ISH) prevalence measurement
Number of subjects: 354
Study 31020550 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors analysis for HT
Number of subjects: 354
Study 31020550 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors analysis for ISH
Number of subjects: 354
Study 27868341 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular synthetic matrix plus standard care (ASM + SC)
Number of subjects: 53